• The company appointed Erik Blum and Adam Falkoff to its board, strengthening finance and strategic leadership.
• The additions come as Olenox completes a year-long repositioning into a vertically integrated energy and infrastructure company.
• Management is prioritizing production optimization and oilfield services over exploration-led growth, aligning its strategy with the broader push for U.S. energy independence.
• Olenox operates across energy development, oilfield services, containerized infrastructure, and industrial monitoring.

Olenox Industries (NASDAQ: OLOX), a vertically integrated energy company, is reinforcing its governance bench as it works to establish itself as a vertically integrated energy and infrastructure platform, announcing the appointment of Erik Blum and Adam Falkoff to its board of directors. The company said the appointments fill existing vacancies and expand board expertise in corporate finance, public policy, and strategic leadership. Details of the changes were disclosed in a Form 8-K filing and summarized in a company announcement earlier this month (https://ibn.fm/YpxM6).

Blum brings more than three decades of experience across corporate finance, debt markets, and public-company management. Most recently, he led the turnaround of a publicly traded firm from non-reporting status to full SEC reporting. 

Falkoff adds a policy and international affairs perspective, with more than 20 years advising Fortune 100 companies and government leaders. He currently runs CapitalKeys, a bipartisan consulting firm, and previously held senior roles at Microsoft and Amazon, as well as positions in the U.S. legislative and executive branches.

Both directors will participate in Olenox’s standard non-employee compensation program, including cash retainers and equity awards, prorated for their February start dates.

The board refresh comes as Olenox completes a significant corporate transition. Formerly known as Safe & Green Holdings Corp., the company rebranded in 2025 to reflect what management describes as a unified operating model rather than a collection of disconnected assets.

Olenox spans energy development, oilfield services, industrial technology, containerized infrastructure, and monitoring systems. Energy sits at the center of the structure, organized into three integrated divisions.

The oil and gas unit focuses on acquiring underdeveloped or distressed properties in Texas, Oklahoma, and Kansas. Rather than pursuing exploration-heavy strategies, Olenox emphasizes improving production from existing wells, a capital-light approach that management says can deliver quicker returns.

Supporting that effort is the company’s oilfield services division, which provides well abandonment and environmental reclamation services to third parties. These activities generate recurring cash flow while also serving Olenox’s own assets, creating operational overlap across the platform.

A third energy-focused unit, Olenox Technologies, develops proprietary tools such as plasma pulse and ultrasonic cleaning systems designed to restore output from underperforming wells.

Outside of upstream operations, Olenox continues to run Giant Containers, a business founded in 2017 that designs and manufactures modular, containerized systems for industrial and commercial applications. These systems are positioned as building blocks for on-site power generation and infrastructure deployments, particularly near pipeline networks or production facilities.

The company also operates Machfu Monitoring, which delivers Industrial Internet of Things capabilities that connect field assets to enterprise systems through secure networks, providing real-time visibility into operations.

The consolidation of these subsidiaries into a single operating structure is meant to improve coordination across divisions and offer investors a more coherent picture of asset performance.

The strategic reset is taking place against the backdrop of renewed focus on American energy independence. Olenox’s emphasis on domestic production, well optimization, and infrastructure services aligns with broader policy and market efforts to strengthen U.S.-based energy supply chains while reducing reliance on imports.

For more information, visit the company’s website at www.Olenox.com.

NOTE TO INVESTORS: The latest news and updates relating to OLOX are available in the company’s newsroom at https://ibn.fm/OLOX

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand.

A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard oncology regimens, but to make established modalities work better by reducing tumor resilience under treatment pressure.

What makes the current setup more distinctive is that LIXTE also owns a hardware platform. In November 2025, LIXTE announced the acquisition of Liora Technologies Europe Ltd., making it a wholly owned subsidiary. Liora’s LiGHT system, short for Linac for Image Guided Hadron Therapy, equips a proton therapy system that uses electronically controlled beam energy rather than mechanical energy degraders.

Why Proton Therapy Still Has a Scale Problem

Proton therapy’s clinical appeal is well known, delivering radiation in a way intended to better spare surrounding healthy tissue compared with conventional photon approaches in certain settings. The challenge has been the practical side: large physical footprints, complex gantry-based designs, long deployment cycles, and high capital intensity. Conventional multi-room proton centers can cost $250 million or more to build and take years to bring online.

LIXTE and Liora’s positioning is that LiGHT is engineered to reduce that burden by changing how energy is set and delivered. In LIXTE’s description of the system, LiGHT uses compact linear accelerator architecture with fast, electronic energy control designed to avoid the inefficiencies of mechanical degraders. A peer-reviewed paper published in Medical Physics describes the LIGHT concept as a CERN spin-off integrating standing-wave linac structures capable of achieving 230 MeV proton acceleration in approximately 24 meters. Professor Steve Myers, former Director of Accelerators and Technology at CERN, has publicly endorsed the system’s potential, noting its capacity to deliver very high dose rates to deep-seated tumors while reducing both installation costs and the number of treatment sessions required.

The numbers Liora has put forward sharpen the commercial argument. According to the company, more than $300 million has been invested to date in developing the LiGHT platform, and a four-treatment-room site is projected to cost approximately $85 million, roughly 30% of comparable competing installations, with a 12-to-18-month build timeline. If that approach proves deployable at scale, the commercial logic is straightforward: expanding access to high-precision radiation depends as much on install time, operational simplicity, and unit economics as it does on clinical performance.

Liora as an Operating Asset, Not Just an R&D Project

LIXTE has described an ambition to pursue recurring economics around jointly operated treatment centers, rather than limiting the opportunity to one-time equipment sales. That framing matters because it ties Liora’s value not only to engineering milestones, but also to site development execution, regulatory pathways, and the company’s ability to partner with operators that can run treatment capacity at high utilization.

LIXTE has also pointed to software-defined capabilities, including the notion that LiGHT could support newer radiation delivery protocols, such as FLASH radiotherapy, through software upgrades alone, with no hardware modifications required. Whether those capabilities translate into adoption will depend on evidence, workflow integration, and the willingness of centers to take on new infrastructure models, but the direction is consistent with a broader trend: oncology platforms increasingly compete on throughput and precision, not only on novel molecules.

LB-100 Development and Near-Term Catalysts

On the drug side, LIXTE has highlighted multiple clinical efforts built around LB-100, including combination approaches intended to increase treatment response. One concrete data point investors have been watching is LIXTE’s clear cell ovarian cancer program. A December 2025 update stated that, after reaching an initial target of 21 patients, the collaborators planned to double enrollment to 42 patients, with MD Anderson and Northwestern cited as participating sites. The company expects initial data from the first 21 patients to be presented in the first half of 2026.

The strategic bridge between the two sides of the business is the potential for tumor sensitization paired with more conformal dose delivery. LB-100 is positioned as a way to make tumor cells less capable of recovering from treatment stress, while LiGHT is positioned to deliver radiation with greater control and precision. LIXTE has explicitly discussed this “drug-device” synergy concept in its communications around the Liora acquisition.

Capital Markets Posture and Visibility

As a small-cap oncology name, market access still matters. LIXTE has used conferences and corporate communications to broaden visibility, including participation in the DealFlow Discovery Conference in late January 2026. The company also completed a $4.3 million registered direct offering in December 2025, underscoring a continued focus on funding operations while advancing both clinical and platform milestones.

The Takeaway

LIXTE is unusual because it is not just pursuing a single therapeutic thesis. It is attempting to build an oncology platform where a sensitizing drug candidate and a modernized proton delivery system can reinforce each other over time. The opportunity is tied to execution on two fronts, clinical progress for LB-100 and commercialization readiness for Liora’s LiGHT system, but the underlying premise fits the current moment in cancer care: better outcomes increasingly require both better biology and better infrastructure.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• SPARC AI recently launched the company’s navigation and target acquisition application on a defense made Tactical Edition smartphone
• The application provides an on-device software layer that offers GPS-denied navigation as well as laser-free target acquisition that uses the phone’s camera
• The company is also planning to register a U.S. subsidiary to support participation in U.S. defense procurement pathways and streamline eligibility for bids and tenders

SPARC AI (CSE: SPAI) (OTCQB: SPAIF), a next-gen developer of target acquisition systems and navigation software, recently launched a fully offline GPS-denied navigation and laser-free target acquisition app on a defense made Tactical Edition smartphone.

Samsung’s Tactical Edition phone is built for military usage and generally acquired through government and enterprise channels, as opposed to being purchased via public retail. SPARC installed the application on a device supplied by Precision Technical Defence.

This application provides on-device software that maintains uninterrupted navigation and enables targeting workflows, even when the phone is operating offline. Being able to offer continuous navigation even when GPS is unavailable or untrustworthy helps support reporting and route execution without depending on being connected to a network.

The app also uses the phones camera for laser-free target acquisition. All an operator needs to do is point the camera at a point of interest and record its geolocation without the need for a laser range finder.

Speaking about this announcement, SPARC AI CEO, Anoosh Manzoori, said that “With nearly every soldier now carrying a mobile device, the opportunity to deploy SPARC AI on phones is on the same order of magnitude as our drone opportunity. Getting there wasn’t straightforward; delivering reliable navigation and target location fully offline, on a standard handset, without extra sensors or bolt-on hardware, is a much harder technical problem than it looks.”

In addition to this mobile application announcement, SPARC also revealed that the company is in the process of registering a subsidiary company in the USA. This subsidiary will support participation in the U.S. defense procurement pathways and also help streamline eligibility for bids and tenders to help SPARC AI sell in the U.S. market.

About SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)

SPARC AI is a company that develops next-gen GPS-free target acquisition systems and navigation software for drones and edge devices. The company’s zero-signature technology delivers real-time tracking and detection, without relying on heavy sensors, lidar, or radar. It has the mission to redefine situational awareness by merging math, AI, and edge computing into a single unified intelligence architecture.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• The first quarter of fiscal 2026 was an important milestone for the company, as it represents the first full reporting period that FWDI operates as the worlds largest Solana (SOL) treasury company.
• The company announced information about treasury holdings, staking performance, financial results, and more.
• FWDI also mentioned several milestones and accomplishments the company has reached, and the goals for the future.

Forward Industries (NASDAQ: FWDI), a SOL treasury company, recently reported the company’s fiscal first quarter 2026 financial and operating results

The first quarter of fiscal 2026 is the company’s first full reporting period as the world’s largest Solana treasury company, and it moved from simply launching the strategy, to actively executing it through market volatility.

As of December 31st, 2025, the company has liquid SOL holdings of 6,962,501 SOL. Since the inception of the strategy, FWDI’s validator infrastructure has generated between 6.5% and 7.2% gross annual percentage yield (“APY”) before fees, which already outperforms many peer validators.

Also as of the end of 2025, the company has generated more than 112,171 SOL in staking rewards, and almost all of FWDI’s SOL holdings are currently staked. The company also had $25.4 million in cash at the end of 2025, and no institutional debt.

The announcement indicated that the company’s revenue for the first quarter of fiscal 2026 increased by more than 4X, going from $4.6 million in the prior-year period, up to $21.4 million. This growth was largely driven by staking revenue that the company generated through the Solana treasury strategy.

Operationally, the company also made steady progress, as it expanded how FWDI participates on the Solana blockchain. First, it launched fwdSOL, the company’s proprietary liquid staking token, which lets FWDI earn native staking yield, while maintaining liquidity and deploying capital across the Solana ecosystem.

The company also began testing a proprietary automated market maker, developed alongside Galaxy, which positions the company to participate directly in on-chain trading activity. These moves highlight the company’s focus on building an operating platform that’s active, scalable, and designed to enhance SOL-per-share over time.

Finally, as Solana continues to be adopted as real financial infrastructure, the company believes FWDI is well-positioned to evolve from a treasury to an active and value-generating business that’s aligned with the growth of the network.

About Forward Industries Inc. (NASDAQ: FWDI)

Forward Industries is building and managing a large-scale Solana (SOL) treasury, and is backed by many of the most influential investors in the digital space. It has acquired more than 6.9 million SOL, and the company’s strategy involves creating value by actively participating in the Solana ecosystem via on-chain opportunities like staking, lending, and engaging in decentralized finance (“DeFi”).

For more information, visit the company’s website at www.ForwardIndustries.com.

NOTE TO INVESTORS: The latest news and updates relating to FWDI are available in the company’s newsroom at https://ibn.fm/FWDI

Disseminated on behalf of Nevada Organic Phosphate Inc. (CSE: NOP) (OTCQB: NOPFF) and may include paid advertising.

• Early drilling at Murdock Mountain project in Nevada shows an average grade of 10.93% P₂O₅ in the Upper Phosphatic Zone, alongside calcium, magnesium, silicon, and trace micronutrients.
• Heavy metals such as cadmium, arsenic, and lead were reported well below common organic certification thresholds.
• Management says the chemistry supports slow-release phosphorus and soil conditioning benefits.
• The company is positioning Murdock Mountain as a potential direct-ship organic phosphate input rather than a conventional chemical fertilizer feedstock.
• Nevada Organic Phosphate aims to advance the project amid rising demand for domestic, low-contaminant fertilizer sources.

Nevada Organic Phosphate (CSE: NOP) (OTCQB: NOPFF), a B.C.-based leader in organic sedimentary phosphate exploration, announced that new assay interpretations from its Murdock Mountain property indicate the material could function as a naturally balanced, multi-nutrient mineral fertilizer aligned with organic and regenerative farming practices (https://ibn.fm/oTvGI).

In a February 10 update, the Vancouver-based explorer reported continued progress analyzing samples from the first six drill holes in the Upper Phosphatic Zone (“UPZ”). The company pointed out that weighted average grades of 10.93% P₂O₅ are now supported by broader geochemical data showing meaningful levels of calcium, magnesium, potassium, iron, manganese, silicon, and trace micronutrients.

Chief executive Robin Dow said the results suggest Murdock Mountain is shaping up as more than a single-nutrient phosphate deposit. “These assay results continue to validate the strategic importance of Murdock Mountain,” Dow said in the release. “We are defining a uniquely clean and naturally balanced phosphate system at a time when growers, distributors, and regulators are all demanding lower-risk nutrient sources. The chemistry we are seeing, with low impurities, meaningful co-nutrients, and slow-release phosphorus, aligns directly with the needs of organic and regenerative agriculture.”

The UPZ is located at Murdock Mountain in northeastern Nevada. Nevada Organic Phosphate is advancing the project as a potential direct-ship raw rock phosphate operation aimed at organic agriculture markets, rather than the conventional chemical fertilizer supply chain.

According to the company, ongoing analysis shows slow-release phosphorus combined with co-nutrients that support soil structure, microbial activity, and long-term fertility; attributes increasingly sought by organic and regenerative growers.

In the update, management highlighted what it described as an “exceptionally clean” impurity profile. Cadmium, arsenic, lead, chromium, and mercury were reported at levels well below typical regulatory limits used by organic certifiers in North America. The company also noted low radionuclide readings, which can be a concern for sedimentary phosphate deposits globally.

Director Garry Smith, P.Geo., said the low contaminant levels reduce certification risk for organic producers and may offer a regulatory advantage as limits tighten in key agricultural markets. “As global contaminant limits tighten, clean phosphate sources are becoming increasingly scarce,” said Smith. “NOP’s low cadmium, low arsenic, and low radionuclide signature reduces regulatory friction for growers and positions the company to compete in premium fertilizer markets where compliance and purity matter.”

The company believes this clean profile differentiates its Nevada material from many commercial phosphate sources that require blending or processing to meet organic standards.

Beyond phosphorus, Nevada Organic Phosphate emphasized the agronomic role of naturally occurring calcium, reported at roughly 29% CaO, as well as magnesium, silicon, zinc, manganese, molybdenum, sulfur, and iron. These elements, management said, appear at concentrations sufficient to provide measurable soil and crop benefits.

While the company does not plan to market the product as a liming agent, it noted that the calcium content could help moderate soil acidity and improve nutrient availability, offering what it called an incidental agronomic benefit for growers.

The UPZ also showed relatively low uranium compared with many sedimentary phosphate deposits worldwide, according to internal benchmarking against U.S., South American, and European data sets referenced in the release.

According to Nevada Organic Phosphate , the Murdock Mountain property is one of the only large-scale organic sedimentary phosphate projects in North America, hosting a phosphate bed extending approximately 6.6 kilometres, with additional applications that could expand the prospective strike length beyond 30 kilometres. The project is located near highway and rail infrastructure linking northeastern Nevada with California, which the company views as advantageous for future logistics.

The company is targeting demand driven by organic food production and regenerative farming practices, as U.S. agriculture is gradually shifting away from highly soluble chemical phosphates toward reactive, naturally occurring mineral inputs that support soil biology.

That shift comes as fertilizer supply chains remain under scrutiny and governments encourage domestic sourcing of critical agricultural inputs. Murdock Mountain can potentially serve as a premium input for growers seeking clean phosphorus combined with secondary nutrients, rather than a bulk commodity feedstock for industrial fertilizer processing.

The current results are based on weighted averages from UPZ intercepts in the first six drill holes, with additional soil and geological work ongoing. Management said future steps will focus on refining target zones and advancing the project toward resource definition, subject to permitting and financing.

“The Upper Phosphatic Zone is demonstrating a remarkably consistent geochemical signature across the first six drill holes,” added Smith. “Calcium, magnesium, silicon, iron, zinc, manganese, and molybdenum all occur at agronomically relevant levels, and the impurity profile remains exceptionally low. This is not a single-nutrient ore body – it is a multi-nutrient mineral input with a clean chemistry advantage that is increasingly rare in global phosphate deposits.”

For more information, visit the company’s website at www.NevadaPhosphate.com.

NOTE TO INVESTORS: The latest news and updates relating to NOP are available in the company’s newsroom at https://ibn.fm/NOP

• The broader wearable technology market has been expanding rapidly as connectivity, health monitoring and intuitive user interfaces drive consumer and enterprise interest
• The company’s vision also anticipates broader adoption beyond gaming, healthcare or fitness applications

The global appetite for more intuitive, seamless interaction with technology is accelerating, and AI-powered, touchless sensing wearables are emerging as a cornerstone of this transformation. Wearable Devices (NASDAQ: WLDS) is at the forefront of this trend, leveraging neural-input interfaces and gesture recognition technology to provide hands-free control solutions that may redefine how users interact with consumer electronics and smart environments. Recent developments from the company highlight both growing market demand and Wearable Devices’ strategic role in unlocking new use cases for touchless wearable technology.

The global wearable technology market is experiencing rapid growth, driven by advances in connectivity, health monitoring, and intuitive user interfaces. According to Research and Markets, the market is expected to expand from approximately $82.33 billion in 2024 to more than $230 billion by 2033, reflecting a compound annual growth rate of about 12.1% as demand rises for AI-enabled wearables with advanced sensors and interaction capabilities.

Gesture recognition and touchless sensing are emerging as critical enablers of next-generation human-machine interaction. Grand View Research estimates the gesture recognition market will grow from roughly $25.44 billion in 2024 to over $70.18 billion by 2030, representing an 18% CAGR. The broader gesture recognition and touchless sensing market is forecast to expand from $28.4 billion in 2025 to nearly $125.9 billion by 2032, driven by adoption across consumer electronics, automotive, and enterprise applications.

This trend is further reinforced by the rapid expansion of extended reality glasses as a core wearable category. According to a December 2025 report by International Data Corporation titled “Global XR Shipments Rebound Behind Glasses-First Momentum, IDC Reports,” global XR glasses shipments are forecast to grow approximately 320% in 2025, reaching 10.6 million units. Growing mainstream acceptance of XR glasses, alongside continued enthusiasm from gamers for mixed reality and large-format experiences, is expected to drive cumulative shipments of approximately 105.7 million devices from 2025 through 2029, with annual shipments reaching about 29.7 million units by 2029 and a projected compound annual growth rate of 29.3%.

At the intersection of these trends stands Wearable Devices, a company dedicated to advancing touchless interaction through neural input interfaces that translate subtle finger movements and hand gestures into device control. The company’s technology centers on a novel approach that enables users to manipulate a wide variety of digital devices, from consumer electronics and smartwatches to augmented and virtual reality headsets, drones and robots, without physically touching a screen or controller. The company’s focus reflects a shift beyond conventional touch or voice input toward a more intuitive, gesture-driven experience, a direction underscored by the broader market’s evolution toward AI integration and natural user interfaces.

The company’s Mudra Link and Mudra Band products illustrate their early traction in both the consumer and enterprise segments. In the first half of 2025, Wearable Devices began recognizing revenue from the Mudra Link, a universal gesture control wearable wristband compatible with both Android and iOS devices, while also continuing to generate revenue from the Mudra Band for Apple Watch. These products expand the company’s reach while demonstrating the practical application of its core technology in real-world use cases.

AI-enabled wearable devices themselves are experiencing rapid growth. A report by the Brainy Insights projects that the global wearable AI market, which includes devices with built-in artificial intelligence capabilities, could expand from approximately $27.06 billion in 2023 to around $289.38 billion by 2033, propelled by consumer demand for advanced functionality such as personalized data insights, on-body intelligence and seamless integration with digital ecosystems. In this context, Wearable Devices focuses on AI-driven gesture recognition and neural input control positions the company to potentially capture a share of a segment that converges sensor innovation with intuitive interaction paradigms. Recent industry developments, including Apple’s acquisition of Q.ai, underscore the growing emphasis on advanced input and interaction technologies. As AI becomes more pervasive in wearables, differentiation is increasingly expected to hinge on intuitive, touchless methods of capturing user intent.

The company’s vision also anticipates broader adoption beyond gaming, healthcare or fitness applications. Gesture-based control and neural interfaces may find applicability in augmented reality glasses, virtual reality platforms, industrial IoT systems and connected environments where hands-free interaction is desirable for safety, convenience or accessibility. As demand for AI-powered, intuitive wearables continues to expand across these diverse sectors, Wearable Devices’ technology could become a foundational component of future user-centric design, particularly as developers and manufacturers seek ways to embed smarter, more responsive interfaces into next-generation devices.

The market for AI-powered, touchless sensing wearables is growing quickly and drawing stronger interest from both consumers and industry, backed by strong projected growth rates across the wearable, gesture recognition and touchless sensing segments. Wearable Devices’ work in neural input interfaces and gesture control technology reflects a broader movement toward more natural human-machine interaction, and its expanding product suite illustrates how companies in this space are responding to evolving demand. With a marketplace that values seamless, intuitive control and advanced AI integration, Wearable Devices is positioning itself to benefit from the wave of innovation sweeping through the wearable technology landscape.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

Disseminated on behalf of LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) and may include paid advertising.

• LaFleur Minerals anticipates the imminent completion of its Preliminary Economic Assessment (“PEA”) to guide its pending gold production at a sprawling site in the renowned Abitibi Greenstone Belt of Eastern Canada
• LaFleur is completing upgrades and refurbishments to get its Beacon Gold Mill operating in the next quarter with feedstock from its nearby Swanson Gold Deposit and potentially other area miners
• The company has 445 mineral claims and one mining lease at the Swanson Gold Project spanning more than 18,000 hectares (about 44,500 acres), hosting multiple gold targets, primarily the key Swanson Gold Deposit
• Company CEO Paul Ténière recently participated in a webinar that addressed the company’s assets, the company’s progress toward production, and its strategic aims

Gold explorer and near-term gold producer LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) is preparing the restart of gold production at its Beacon Gold Mill as a processing outlet for company feedstock sourced from its nearby Swanson Gold Deposit in the celebrated Abitibi Gold Belt of Eastern Canada, where more than 300 million ounces of gold have been produced historically or accounted for with current reserve estimates (https://ibn.fm/RZlLz).

“(The mill) has a name plate of 750 (tonnes per day of production capacity), but we are looking at upgrades and refinements to get that to at least 1,000 tonnes or more per day,” LaFleur CEO Paul Ténière said during a Feb. 10 webinar broadcast by Red Cloud Securities (https://ibn.fm/t5FLD). “It is able to process gold, silver, and even a little bit of base metals as well, so it can handle multi-element-type deposits. We’re fully permitted at the mill but also at the tailings storage facility for up to 1.8 million tonnes of tailings.”

LaFleur obtained the idled gold mill at a bargain price in bankruptcy proceedings a few years ago, and the mill has become a key asset thanks in part to its access to power structure and skilled labor in the heavily explored and prolific gold belt.

“The mill’s barely run since it was opened, so I would say there’s at least over 90% of capacity still left,” Ténière said. “And at the current rate that we’re looking at, we’re looking at about nine years of life for that tailings storage facility. So all of that has been kept up since we took over the asset.”

The company aims to run a 100,000-tonne bulk sample from the Swanson Gold Deposit and then build into a larger operation, and is awaiting a Preliminary Economic Assessment (“PEA”) that will provide further guidance on its plans.

“I was hoping that they (the PEA results) would be out by the time of having this discussion, but shortly they will be coming out and then we’ll be able to get a lot more detail into the economics and also the mine plan,” Ténière said.

Plans to add a dedicated rail spur through the Swanson Property and the Beacon Gold Mill site to facilitate efficient loading and transport of material would provide the company with a significant economic benefit through reduced hauling costs, decreased pollutants and increased safety by reducing truck traffic through nearby villages if such an agreement with government and railway officials can be successfully reached.

LaFleur has built its available capital through $7.8 million in financing to restart gold production at the mill (https://ibn.fm/YhlEG), which comes at a strategic inflection point as the company shifts from being primarily an explorer toward gold production and revenue generation. This transition is typically one of the hardest and most capital-intensive phases for a junior mining company and having secured sufficient funding at this moment is crucial for moving from planning into actual operations, and it seems that LaFleur has done this seamlessly. The LIFE and flow-through offerings were upsized and oversubscribed showing strong investor interest and confidence in LaFleur’s plans and assets, and funds the restart of a fully permitted mill and materially reduces execution risk at a pivotal stage in its development.

“Primarily we’re looking at Beacon to process ore from our own deposits, and we’re also looking to generate cash as quickly as possible after we’ve completed the upgrades and refurbishments,” Ténière said. “Initially we’re looking a bulk sample of 100,000 tonnes — could get up to about 4,200 ounces of gold out of that, and could be even more depending on our cutoff. But we are looking to have that going fairly quickly. Because Swanson sits on a mining lease, there’s a lot less permitting required.”

For more information, visit the company’s website at LaFleurMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to LFLRF are available in the company’s newsroom at https://ibn.fm/LFLRF

Qualified Person Statement:

All scientific and technical information contained in this article has been reviewed and approved by Louis Martin, P.Geo. (OGQ), Exploration Manager and Technical Advisor of the company and considered a Qualified Person for the purposes of NI 43-101.

• WLDS recently announced a strategic partnership with Rokid to enable neural, touch-free control for AI and AR smart glasses
• Wearable Devices Ltd. Operates at the nexus of artificial intelligence, neural sensing, and intuitive human-computer interaction
• These updates highlight the company’s broader mission: to redefine the way users interact with AI-powered wearables via natural, frictionless neural input

Wearable Devices (NASDAQ: WLDS) continues to venture into new frontiers with its proprietary neural interface technology, strategically targeting the quickly evolving smart glass and augmented reality market. In a recent announcement, the company made public its collaboration with Rokid, a leading force in human-computer interaction and AR glasses, to deliver seamless, wrist-based gesture control for Rokid’s AI and AR eyewear (ibn.fm/2mobH).

Under the partnership, WLDS’s Mudra Link neural wristband can now work with Rokid Glasses, enabling pre-mapped gestures, out-of-the-box pairing, and a seamless onboarding experience. Both companies plan to implement a joint marketing approach, as well as a consumer bundle rollout, in the second quarter of 2026.

With AI-powered smart glasses gaining wider acceptance, input remains one of the difficulties faced by the category. Although software and hardware capabilities like navigation, real-time translation, and transcription have evolved quickly, intuitive control is still not catching up quickly enough. Wearable devices are trying to solve the challenge by transforming subtle neural signals from the wrist into reliable, touch-free commands, making it possible for users to interact naturally without using touchpads, external controllers, or voice prompts.

The company already carries a solid reputation as a force in the AI-enabled wearables sector through its Mudra Link and Mudra Band products. These products enable gesture-based interaction across a broad range of platforms such as smartwatches, smartphones, VR headsets, AR glasses and other Bluetooth-enabled devices. The partnership with Rokid underscores the scalability of Wearable Devices’ technology, placing it as a foundational input layer for the entire wearable solutions ecosystem.

This strategic direction is further validated by recent moves from leading global technology companies, including Apple’s acquisition of Q.ai for approximately $2 billion. The transaction highlights a growing industry focus on the interface and input layer as the next major battleground for AI-driven devices. As artificial intelligence becomes increasingly embedded in wearables, spatial computing platforms, and ambient systems, the ability to capture user intent through natural, frictionless input is emerging as a key differentiator. Apple’s investment in silent and micro-expression-based interaction reinforces the view that future AI value creation will extend beyond software models to the foundational technologies that enable intuitive, hands-free, and context-aware user interaction, directly aligning with the long-term direction of advanced wearable ecosystems.

Looking ahead to 2026, the company intends to build on this momentum and redefine the boundaries of human-machine interaction through its emerging AI initiatives. Beyond gesture recognition, the company is advancing its proprietary Large MUAP Model (“LMM”) and edge AI capabilities with the goal of supporting a new neural standard for the AI era. The company’s technology is designed to embrace the latest AI innovations, introducing” Vibe Coding” tools accessible to developers, alongside autonomous agent-based workflows utilized by the company to accelerate further development. By processing intent directly on the wrist, the company aims to ensure that as digital systems become smarter, user control remains seamless and intuitive.

These latest updates highlight Wearable Devices’ broader mission: to redefine human-computer interaction by making control intuitive, effortless and invisible. From neural interfaces that adapt to individual users to gesture based inputs for AI glasses, WLDS is creating the needed framework that makes it possible for intelligent devices to be used in everyday life.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

• LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100
• Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit
• These two announcements paint a picture of a company advancing on multiple fronts

LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore its involvement in community health initiatives through its sponsorship of the Good Health: Mind, Body & Soul Summit.

Last week, LIXTE outlined advances in its approach to cancer therapy through its proprietary compound LB-100, which works by inhibiting Protein Phosphatase 2a (“PP2A”), an enzyme involved in cell growth regulation, DNA repair and immune modulation. The company described this mechanism as a “novel approach to enhancing cancer therapy,” positioning LB-100 as a potential amplifier of existing chemotherapies and immunotherapies rather than a standalone agent.

The release explains that, by targeting PP2A, LB-100 may make tumor cells more susceptible to treatment, promoting stronger immune responses and enhancing the effects of existing therapies. This strategy reflects a broader trend in oncology to improve outcomes by augmenting established treatment regimens rather than relying solely on new cytotoxic agents. LB-100 has shown evidence of tolerability and anticancer activity in early clinical settings, and LIXTE continues to pursue clinical evaluation in multiple tumor types.

Clinical programs for LB-100 have drawn attention because they explore its use not only in combination with traditional chemotherapies but also alongside modern immunotherapies, which are transforming cancer care for many patients. The company’s emphasis on PP2A inhibition aligns with its broader oncology strategy, which has been documented in other industry and investor resources as a unique therapeutic approach within precision oncology.

Alongside clinical development news, LIXTE announced that it is sponsoring the Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit, rooted in the legacy and music of hip-hop group De La Soul, is designed to explore health-equity issues impacting Black men and their families, bringing together leaders in health, culture, science and community to discuss a wide range of topics including cancer, heart disease, mental health and overall wellness.

According to the company, the summit aligns with LIXTE’s mission as a clinical-stage pharmaceutical company advancing cancer care through LB-100, as well as the work of its European subsidiary LIORA Technologies. The company’s sponsorship underlines its recognition that scientific progress must be paired with community engagement and awareness, particularly for populations that historically experience health disparities.

The Good Health summit will feature discussions on disease prevention, treatment access, mental well-being and generational health themes, aiming to foster a space where medical science and lived experience intersects. By participating in such initiatives, LIXTE is extending its influence beyond drug development into conversations about how healthcare systems and scientific innovation can better serve underrepresented communities. This integration of clinical ambition with social advocacy reflects a broader trend among biotechnology firms to address both scientific and societal dimensions of illness and treatment.

Taken together, these two announcements paint a picture of a company advancing on multiple fronts. On the scientific side, LIXTE’s work with LB-100 represents an innovative angle in oncology drug development, not by creating yet another cytotoxic agent but by enhancing the performance of existing therapies and potentially increasing their effectiveness. This approach may appeal to clinicians and researchers looking for ways to improve outcomes for patients with resistant or hard-to-treat cancers.

On the community engagement side, sponsoring the Good Health Summit positions LIXTE as an organization aware of the broader context in which cancer care and general health services are delivered. By aligning its corporate mission with an event focused on health equity, the company is helping draw attention to disparities that impact access, outcomes and public understanding of disease. This reflects an understanding within the broader pharmaceutical industry that scientific innovation and community engagement are mutually reinforcing aspects of long-term success.

Looking ahead, developments such as advances in LB-100’s clinical programs and participation in community health initiatives could help LIXTE shape its identity not just as a biotech developing a promising oncology compound but as a company engaged in the broader dialogue of health equity. For investors, clinicians and patients alike, these dual narratives of scientific progress and social engagement may help position LIXTE as a company aware of both the technical and human sides of modern healthcare.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

• ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance.
• The company’s core operations focus on the health and wellness sector via a vertically integrated portfolio.
• ETST’s mission centers on building durable shareholder value through regulatory discipline, operational control, and scalable growth platforms.

A Hands-On Approach to Portfolio Management

Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.

Through its wholly owned subsidiaries, ETST operates a vertically integrated network that includes high-quality compounding pharmacies, telemedicine platforms, and specialized healthcare facilities. This “driver’s seat” approach allows the company to dictate strategy, streamline capital allocation, and ensure rigorous regulatory compliance-critical factors in today’s complex healthcare landscape.

Capitalizing on the Digital Healthcare Revolution

ETST’s primary operations are positioned at the intersection of telemedicine and pharmaceutical service sectors experiencing a surge in demand driven by digital transformation and an aging population.

As the global healthcare market shifts toward tech-powered, cost-efficient delivery, ETST’s telemedicine platforms are uniquely positioned to scale. By focusing on businesses that can navigate complex regulatory environments, the company ensures that its growth is not just rapid, but resilient.

Diversification and Operational Excellence

Beyond healthcare, ETST’s portfolio extends into strategic real estate and consumer-focused markets. This multi-faceted approach provides a dual benefit:

• Balance Sheet Stability: Real estate holdings provide asset-backed value and financial grounding.
• Margin Expansion: Consumer-centric ventures offer high growth potential when paired with ETST’s centralized management and branding strategies.

The Path Forward: Methodical Growth

The firm’s acquisition philosophy targets businesses with clear operational improvement and sustainable revenue. By prioritizing practical, methodical growth over speculative expansion, the company mitigates risk while positioning its subsidiaries for measurable impact.

Through centralized oversight and standardized governance, Earth Science Tech is building a resilient platform capable of navigating market cycles and capturing emerging opportunities in essential industries.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST